Specific Carbonylbisimino Compounds for the Treatment of Immune Diseases

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the use of specific carbonyl-bis(imino) compounds, including their enantiomers, diastereomers, and pharmaceutically acceptable esters or salts, as medications for both the treatment and prevention of immune diseases, cardiovascular disorders, diseases related to erythropoiesis (red blood cell production), and for immunization purposes. The core of the invention is the discovery that these compounds can selectively activate the P2Y11 receptor (a G-protein coupled receptor), providing immunosuppressive or immune-modulatory effects with low toxicity and good metabolic stability. They are suitable for oral or injectable administration and are effective at low doses without significant side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of autoimmune diseases such as multiple sclerosis, Crohn’s disease, colitis ulcerosa, lupus, and more.
• Prevention and treatment of organ or tissue transplant rejection (as an immunosuppressive agent).
• Use as an adjuvant to promote immune tolerance during immunization protocols.
• Management of cardiovascular diseases, including heart failure and coronary heart disease.
• Stimulation or support of erythropoiesis in conditions like anemia related to cancer, kidney disease, or blood disorders.
• Potential use in allergic disorders to modulate pathological immune responses.

BenefitsContent extracted from patent full text and abstract with AI.

• Low or negligible toxicity, making long-term or high-dosage treatment safer for patients.
• Good metabolic stability, surpassing natural ligands like ATP, enabling more controlled and lasting therapeutic effects.
• Selective activation of P2Y11 receptor, reducing the risk of off-target side effects from non-specific receptor activation.
• No significant side effects observed in preclinical studies, increasing patient safety.
• Effective at low concentrations and suitable for oral administration, improving patient compliance.
• Potentially non-overdosa-ble due to allosteric activation properties, allowing safer dosing strategies.
• Versatility in pharmaceutical form, allowing use as salts or esters to optimize bioavailability and administration routes.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the use of special carbonyl-bis imino compounds and/or the enantiomers, diastereomers, and pharmaceutically compatible esters and/or salts thereof, to produce medication for the therapeutic and/or prophylactic treatment of diseases selected from the group comprising immune diseases, cardiovascular diseases, diseases related to erythropoietic disorders, and/or for immunization.